Young R N
Merck Frosst Canada Inc., Quebec, Canada.
Agents Actions Suppl. 1988;23:113-9. doi: 10.1007/978-3-0348-9156-1_7.
L-648,051 (I) is a potent, competitive and selective antagonist of the leukotriene D4 receptor in guinea pig and human lung tissue. Its activity on isolated smooth muscle preparations and its superiority relative to other agents (L-649,923 (II) or FPL 55712) in reversing ongoing contraction to LTD4 was somewhat unexpected in light of the results of receptor binding studies (Ki = 6.2 microM for L-648,051 versus 0.4 microM for L-649,923 and 2.0 microM for FPL 55712 on guinea pig lung membranes). The reasons for this observed superiority are unknown but may relate to the rate at which various antagonists equilibrate with the leukotriene receptors on various tissues. The physical properties (polarity) of L-648,051 may contribute to this enhanced rate of equilibration. The rapid metabolism and elimination of L-648,051 in vivo should be an advantage for a topical agent by minimizing systemic exposure. The potential role for L-648,051 as a novel aerosol therapy for asthma is now being investigated.
L-648,051(I)是豚鼠和人肺组织中白三烯D4受体的强效、竞争性和选择性拮抗剂。鉴于受体结合研究的结果(L-648,051对豚鼠肺膜的Ki = 6.2微摩尔,而L-649,923为0.4微摩尔,FPL 55712为2.0微摩尔),它对离体平滑肌制剂的活性及其相对于其他药物(L-649,923(II)或FPL 55712)在逆转对LTD4的持续收缩方面的优势有些出人意料。这种观察到的优势的原因尚不清楚,但可能与各种拮抗剂与不同组织上的白三烯受体平衡的速率有关。L-648,051的物理性质(极性)可能有助于提高平衡速率。L-648,051在体内的快速代谢和消除通过最小化全身暴露对于局部用药来说应该是一个优势。目前正在研究L-648,051作为哮喘新型气雾剂疗法的潜在作用。